Transplantation and Cellular Therapy Meetings | Conference

Dr. Locke on the ZUMA-1 Trial of KTE-C19 for Lymphoma

February 26th 2017

Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.

Dr. Scott on Conditioning Regimens for Stem Cell Transplants

February 26th 2017

Bart Scott, MD, Fred Hutchinson Cancer Research Center, explains the importance of the intensity of conditioning for stem cell transplants.

Robert Korngold on Advances in Bone Marrow Transplant

February 25th 2017

Robert Korngold, PhD, John Theurer Cancer Center looks back on the advances we've made so far in bone marrow transplant.

Vaccine Limits Herpes Zoster Infections Following Stem Cell Transplant

February 25th 2017

Treatment with an inactivated varicella zoster virus vaccine, known as V212, lowered the cumulative incidence rate of herpes zoster infection and complications for patients undergoing autologous hematopoietic stem cell transplantation.

Outcomes Have Improved Over Time in Myeloma Patients Relapsing Early After ASCT

February 25th 2017

Rates of early relapse post-autologous stem cell transplant in patients with relapsing multiple myeloma have not changed over time, but post-relapse survival among early relapsers has improved for patients transplanted after 2005 and for those relapsing since 2008.

Dr. Lancet on CPX-351 Compared to Chemotherapy for Older Adults With AML

February 25th 2017

Dr. Lancet of Moffitt Cancer Center explains the use of CPX-351 treatment compared to induction chemotherapy, for older adult patients with acute myeloid leukemia.

Dr. Kebriaei on the Iomab-B Clinical Trial

February 25th 2017

Partow Kebriaei, MD, discusses the Iomab-B clinical trial for older patients with acute myeloid leukemia.

Carfilzomib Maintenance Improves Response Following Transplant in Relapsed Multiple Myeloma

February 25th 2017

According to data from a phase I/II clinical trial, carfilzomib can be safely combined with melphalan in a conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma.

CPX-351 Offers Potential Bridge to Transplant for Secondary AML

February 23rd 2017

More patients with acute myeloid leukemia could proceed to transplant following treatment with CPX-351 compared with the traditional 7+3 chemotherapy regimen.